Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S. Koshkin, Brian I. Rini, JoAnn Hsu et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 184
Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew Leonard Laccetti, Matthew T. Campbell, Benjamin Garmezy et al.|Cancer Medicine|2021Cited by 19
Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).Anika Agarwal, Tian Zhang, Jennifer L. Modliszewski et al.|Journal of Clinical Oncology|2020Cited by 8
Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.Andrew J. Armstrong, Daniel J. George, Santosh Gupta et al.|Journal of Clinical Oncology|2018Cited by 1